Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Privacy Policy

Thank you for visiting the Avalanche Biotechnologies website and for reviewing our privacy policy. The following statement explains our policy regarding personal information you may supply when visiting our website: Avalanche Biotechnologies does not sell, rent, or share information with any other organization. We do not transfer information for any promotional or marketing purposes, nor is that information shared with any third parties whatsoever. Our website contains links to other sites. We are not responsible for the privacy practices of these websites.

Avalanche Biotechnologies, Inc. Reports Second Quarter 2014 Financial Results

September 11, 2014

MENLO PARK, Calif., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014.

Read More

Read All Avalanche News